Prothena Corporation plc
General ticker "PRTA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $549.5M (TTM average)
Prothena Corporation plc follows the US Stock Market performance with the rate: 18.4%.
Estimated limits based on current volatility of 2.5%: low 9.09$, high 9.56$
Factors to consider:
- Total employees count: 163 (-5.8%) as of 2024
- Top business risk factors: Climate change and natural disasters, Cybersecurity threats, Third-party risks, Intellectual property risks, Pandemic risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.03$, 17.19$]
- 2026-12-31 to 2027-12-31 estimated range: [6.27$, 15.52$]
Financial Metrics affecting the PRTA estimates:
- Negative: with PPE of -2.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -32.07 <= 0.01
- Positive: Investing cash flow per share per price, % of -0.03 > -0.63
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 85.82 > 64.29
Short-term PRTA quotes
Long-term PRTA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $91.37MM | $135.16MM | $9.68MM |
| Operating Expenses | $282.41MM | $289.72MM | $194.24MM |
| Operating Income | $-191.04MM | $-154.56MM | $-184.56MM |
| Non-Operating Income | $30.56MM | $25.63MM | $-16.27MM |
| R&D Expense | $220.57MM | $222.52MM | $134.85MM |
| Income(Loss) | $-160.48MM | $-128.93MM | $-200.83MM |
| Taxes | $-13.45MM | $-6.62MM | $43.26MM |
| Profit(Loss)* | $-147.03MM | $-122.31MM | $-244.09MM |
| Stockholders Equity | $561.37MM | $486.93MM | $280.47MM |
| Assets | $696.38MM | $547.11MM | $326.80MM |
| Operating Cash Flow | $-133.91MM | $-150.05MM | $-163.58MM |
| Capital expenditure | $2.81MM | $0.30MM | $0.14MM |
| Investing Cash Flow | $-2.77MM | $-0.30MM | $-0.14MM |
| Financing Cash Flow | $45.10MM | $1.55MM | $-0.14MM |
| Earnings Per Share** | $-2.76 | $-2.27 | $-4.53 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.